Canada markets closed

Pacific Biosciences of California, Inc. (PACB)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
3.1700-0.2100 (-6.21%)
At close: 04:00PM EDT
3.1900 +0.02 (+0.63%)
After hours: 07:59PM EDT

Pacific Biosciences of California, Inc.

1305 O’Brien Drive
Menlo Park, CA 94025
United States
650 521 8000

IndustryMedical Devices
Full Time Employees796

Key Executives

NameTitlePayExercisedYear Born
Mr. Christian O. Henry M.B.A.President, CEO & Director1.1MN/A1968
Ms. Susan G. KimChief Financial Officer564.87kN/A1977
Mr. Mark Van OeneChief Operating Officer772.11kN/A1973
Mr. Jeff EidelChief Commercial Officer435.62kN/A1977
Dr. Stephen Turner Ph.D.Co-Founder341.25kN/A1968
Ms. Michele Farmer CPAVP & Chief Accounting OfficerN/AN/A1980
Trevin RardHead of Investor RelationsN/AN/AN/A
Dr. Brett Atkins J.D., Ph.D.General Counsel & Corporate SecretaryN/AN/AN/A
Ms. Natalie WelchChief People OfficerN/AN/AN/A
Dr. Denis Zaccarin Ph.D.Senior Vice President of Research & Development510.77k4.34M1966
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, it provides revio system + sequel systems which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. The company serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. It markets its products through a sales force and distribution partners in Asia, Australia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.

Corporate Governance

Pacific Biosciences of California, Inc.’s ISS Governance QualityScore as of April 1, 2024 is 5. The pillar scores are Audit: 6; Board: 3; Shareholder Rights: 4; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.